EYE PCR was represented at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress, held at the Hong Kong Convention and Exhibition Centre from February 5–8, 2026 - one of the largest gatherings of eye care professionals in the Asia-Pacific region.

fixOflex Presentation: Advanced IOL Fixation Techniques
Dr. Santaro Noguchi, Medical Advisor at EYE PCR and IOL specialist at ASUCA Eye Clinic in Sendai, Japan, delivered an invited presentation in the symposium on Advanced IOL Fixation Techniques (Session 0224, Convention Hall A-B). His talk, titled *"Dead Bag Syndrome, Single Piece Acrylic IOL in Anterior Vitreous, a New Capsular Device (FixOflex),"* demonstrated the clinical application of fixOflex as a capsular reconstruction device in cases of dead bag syndrome with single-piece acrylic IOL dislocation into the anterior vitreous.
Dr. Noguchi's presentation highlighted the growing body of clinical experience with fixOflex in complex anterior segment cases, building on his extensive track record of fixOflex procedures at ASUCA Eye Clinic.

CE Mark Milestone
The APAO 2026 presentation follows closely on the achievement of CE Mark certification for fixOflex under EU MDR 2017/745, supported by clinical evidence from a 121-patient prospective study conducted in Alexandria, Egypt. The study demonstrated a PCO incidence of just 0.83% at 12 months, compared to 13.0% in the control group - representing a statistically significant reduction in the most common complication following cataract surgery.

Professor Ioannis Pallikaris at APAO 2026
Professor Ioannis Pallikaris, founder of EYE PCR, also delivered an invited presentation at the congress:
"Post-Cataract IOL Exchange in Patients With Keratoconus and Irregular Corneas" - Session 0241: Therapeutic Refractive Surgery (Theatre 2, February 5)

Professor Pallikaris's presentation reflected the broader scope of innovation emerging from the EYE PCR research ecosystem, spanning IOL management in complex corneal cases.

Looking Ahead
EYE PCR continues to expand the clinical evidence base for fixOflex and to engage with the global ophthalmic community through leading international congresses. With CE Mark certification now secured, the company is advancing plans for European market introduction and further clinical adoption.

For professional use only. Refer to Instructions for Use (IFU) for complete indications, contraindications, and warnings.